Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ARWR. HC Wainwright reissued a "buy" rating and set a $110.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 14th. Piper Sandler cut their target price on Arrowhead Pharmaceuticals from $89.00 to $72.00 in a research report on Wednesday, May 11th. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research report on Friday, August 5th. Robert W. Baird upgraded shares of Arrowhead Pharmaceuticals from a "neutral" rating to an "outperform" rating and cut their price objective for the company from $71.00 to $60.00 in a research report on Wednesday, May 11th. Finally, The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the company a "buy" rating in a research note on Monday, August 8th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $70.83.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock traded down $0.66 during mid-day trading on Friday, hitting $43.35. The company's stock had a trading volume of 1,229 shares, compared to its average volume of 697,884. Arrowhead Pharmaceuticals has a one year low of $26.81 and a one year high of $84.83. The company has a 50 day moving average of $39.61 and a 200-day moving average of $41.60. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.37 and a current ratio of 3.37.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). Arrowhead Pharmaceuticals had a negative return on equity of 36.05% and a negative net margin of 61.58%. The company had revenue of $32.41 million during the quarter, compared to the consensus estimate of $52.61 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company's revenue for the quarter was down 29.4% on a year-over-year basis. On average, sell-side analysts forecast that Arrowhead Pharmaceuticals will post -1.08 earnings per share for the current year.